Traws Pharma, Inc. — Director's Dealing 2022

Feb 9, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Onconova Therapeutics, Inc. (ONTX)
CIK: 0001130598
Period of Report: 2022-02-07

Reporting Person: Fruchtman Steven M (Director, President, Chief Executive Off)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-02-07	Stock Option (right to purchase)	$1.82	A	191880	Acquired	2032-02-07	Common stock (191880)	Direct
2022-02-07	Restricted Stock Units	$	A	63960	Acquired		Common stock (63960)	Direct

Footnotes

F1: These options vest over three years, one-third on the first anniversary of the date of grant and thereafter in 24 equal monthly installments over the following two years.

F2: These restricted stock units vest over 3 years from the date of grant: 33% on the first anniversary; 33% on the second anniversary; and 34 % on the third anniversary.

F3: Each restricted stock unit is convertible into one share of common stock.